Polynucleotides
Polynucleotides and surgical scars: why timing and scar type matter
Research on established depressed scars and early postoperative scars uses different products and treatment timings, so the findings cannot be combined into one standard polynucleotide scar protocol.
A surgical scar is not one fixed condition
Scars change as a wound heals and matures. A fine-line scar may gradually flatten and fade, while a hypertrophic scar becomes raised but stays within the original wound. A keloid can grow beyond it, and an atrophic scar sits below the surrounding skin. Redness, tightness, pigmentation, pain and contour may also need different approaches.
This distinction matters before considering polynucleotides. An injection intended for a fully healed, depressed scar is not the same as treatment around a new surgical wound. The NHS advises that scars can continue to fade for two years or more, and no procedure can promise to remove one completely.
What does the study of established depressed scars show?
A 2025 exploratory study reviewed women with moderate-to-severe depressed scars after breast surgery. Treatment began at least six months after surgery and involved five sessions of one highly purified polynucleotide gel. Scar scores and measured surface roughness improved over six months, and both participants and investigators reported improvement.
However, the study was retrospective and had no untreated or alternative-treatment control group. Natural scar maturation, changes in skincare, expectation and measurement variation therefore cannot be separated confidently from the injections. The authors also reported financial relationships with the product manufacturer and other aesthetic companies. The findings support further research, not a universal protocol.
Early postoperative evidence answers a different question
A randomised trial studied 44 people after thyroid surgery. One group received two injections of polydeoxyribonucleotide, or PDRN, on the first two days after surgery; the other group received no injections. At three months, several measures—including redness, scar height and symptoms—favoured the injection group, although the difference in the overall modified Vancouver Scar Scale narrowly missed conventional statistical significance.
This trial concerned immediate postoperative care under a surgical research protocol, not routine treatment of an old cosmetic scar. PDRN and polynucleotide gel are related but not interchangeable terms, and results from one formulation, dose, body site and timing cannot be transferred automatically to another. An aesthetic clinic should not inject a fresh surgical wound without appropriate coordination and a clear clinical indication.
The wider evidence is still small and varied
A 2026 systematic review found seven randomised PN or PDRN trials involving 183 participants across skin rejuvenation, scar prevention and wound healing. Only one trial addressed postoperative scar prevention. Products, schedules and outcome measures differed, so the review could not establish a best scar type, product, injection technique or treatment interval.
Scar improvement also does not mean complete correction. Colour, thickness, tethering and discomfort may respond differently, and a measured score may not equal a noticeable change in daily life. Silicone gel or dressings, massage after full wound healing, sun protection, camouflage, specialist medical treatment or simply more time may be more appropriate.
Downtime and possible adverse effects
Injections into or around a mature scar can cause stinging, tenderness, redness, swelling, itching, small raised points, pinpoint bleeding or bruising. Needling may temporarily make the area look more inflamed. Small studies cannot reliably identify uncommon complications, and the absence of reported serious events does not make treatment risk-free.
Increasing pain, spreading redness or warmth, pus, fever, wound opening, unusual skin colour, marked swelling or a new loss of sensation needs prompt assessment. The NHS recommends urgent advice for a scar that is swollen, painful, warm or producing pus. Active infection, an incompletely healed wound or unexplained change should be assessed rather than treated cosmetically.
Suitability and consultation must be individual
Consultation should document the operation and date, wound-healing history, scar type, symptoms, previous keloids, medical conditions, medicines, allergies, pregnancy or breastfeeding and earlier scar treatments. Product ingredients and source matter, including fish allergy where relevant. Permission to contact the surgical team may be appropriate when healing is recent or the diagnosis is uncertain.
The practitioner should explain which study, if any, resembles the proposed treatment; likely limitations; alternatives; total number of sessions; downtime; cost and follow-up. GMC guidance requires clear discussion of risks and lower-risk options. Choosing observation, established scar care or specialist referral is reasonable when the scar is still changing or the evidence does not support the hoped-for result.
Research and further reading
- 2025 exploratory study of polynucleotides for established postsurgical depressed scars ↗
- Randomised trial of early postoperative PDRN after thyroid surgery ↗
- 2026 systematic review of randomised PN and PDRN trials ↗
- NHS guidance on scar types, natural history and treatment ↗
- GMC guidance on risks, alternatives and follow-up for cosmetic interventions ↗